Pathogenic fungi are a potential threat for infection and death in immunocompromised individuals, recipients of chemotherapy, and other hospital patients. The WHO has identified Candida albicans, Candida auris, Aspergillus fumigatus, and Cryptococcus neoformans as being of critical importance among fungal pathogens. Since many fungal pathogens are drug-resistant or form protective biofilms, it is important to consider novel therapeutic targets that play a role in fungal pathogenesis, such as the Arp2/3 complex. The Arp2/3 complex is the branched actin nucleation factor that promotes actin polymerization, which in turn plays a critical role in these pathogens' normal biology and the formation of biofilms. This project aims to identify compounds that specifically inhibit fungal Arp2/3 complexes. The fungal Arp3 subunit contains 2 amino acid substitutions within the binding pocket for a previously identified mammalian Arp2/3 complex inhibitor. In silico screening was conducted using the structure of Arp3, with several compounds being identified as potential binding partners to fungal Arp3. Here, I describe my use of reconstituted actin polymerization assays to identify a novel lead compound with inhibition activity and specificity to fungal Arp2/3 complexes.
Metrics
40 Record Views
Details
Title
Development of novel fungal Arp2/3 complex inhibitors
Creators
Ana May Dumitrescu
Contributors
Shae B. Padrick (Advisor)
Awarding Institution
Drexel University
Degree Awarded
Master of Science (M.S.)
Publisher
Drexel University; Philadelphia, Pennsylvania
Number of pages
ix, 108 pages
Resource Type
Thesis
Language
English
Academic Unit
Biochemistry and Molecular Biology; College of Medicine; Drexel University
Other Identifier
991021874814504721
Research Home Page
Browse by research and academic units
Learn about the ETD submission process at Drexel
Learn about the Libraries’ research data management services